Cancer pharmacogenomics and pharmacoepidemiology: Setting a research agenda to accelerate translation

Journal of the National Cancer Institute

Volumn 102, Issue 22, 2010, Pages 1698-1705

  Freedman, Andrew N ^a   Sansbury, Leah B ^a   Figg, William D ^a   Potosky, Arnold L ^b   Weiss Smith, Sheila R ^c   Khoury, Muin J ^d   Nelson, Stefanie A ^a   Weinshilboum, Richard M ^e   Ratain, Mark J ^f   McLeod, Howard L ^g   Epstein, Robert S ^h   Ginsburg, Geoffrey S ⁱ   Schilsky, Richard L ^f   Liu, Geoffrey ^j   Flockhart, David A ^k   Ulrich, Cornelia M ^l,m   Davis, Robert L ⁿ   Lesko, Lawrence J ^o   Zineh, Issam ^o   Randhawa, Gurvaneet ^p   Ambrosone, Christine B ^q   Relling, Mary V ^r   Rothman, Nat ^a   Xie, Heng ^s   Spitz, Margaret R ^t   Ballard Barbash, Rachel ^a   Doroshow, James H ^a   Minasian, Lori M ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^d NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^e Mayo Clinic   (United States)

^f UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^g University of North Carolina   (United States)

^h Medco Health Solutions   (United States)

ⁱ DUKE UNIVERSITY   (United States)

^j UNIVERSITY OF TORONTO   (Canada)

^k INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^m Fred Hutchinson Cancer Research Center   (United States)

ⁿ Center for Health Research   (United States)

^o CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^p AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^q ROSWELL PARK CANCER INSTITUTE   (United States)

^r ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^s NATIONAL INSTITUTES OF HEALTH   (United States)

^t UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DASATINIB; ERLOTINIB; FLUOROURACIL; GEFITINIB; IMATINIB; IRINOTECAN; MERCAPTOPURINE; PANITUMUMAB; TAMOXIFEN; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BIOINFORMATICS; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; DEMOGRAPHY; DRUG EFFECT; DRUG EFFICACY; GENETIC MARKER; HUMAN; LIFESTYLE; LUNG CANCER; MEDICAL ETHICS; MEDICAL INFORMATION; MEDICAL RESEARCH; NOTE; OBSERVATIONAL STUDY; PHARMACOEPIDEMIOLOGY; PHARMACOGENOMICS; POPULATION RESEARCH; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; DRUG APPROVAL; DRUG DESIGN; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INDIVIDUALIZED MEDICINE; INFORMATION DISSEMINATION; MUTATION; NEOPLASMS; PHARMACOEPIDEMIOLOGY; PHARMACOGENETICS; PRIVATE SECTOR; PUBLIC SECTOR; RETROSPECTIVE STUDIES; SURVIVORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 78649371176     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq390     Document Type: Note

References (36)

1. Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer. 2009;9(8):576-586.
2. Palomaki GE, Bradley LA, Douglas MP, et al. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Evaluation of Genomic Applications in Practice and Prevention Working Group. Genet Med. 2009;11(1):15-20.
3. Dahabreh IJ, Linardou H, Siannis F, et al. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2010;16(1): 291-303.
4. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to geftinib therapy. Science. 2004;304(5676): 1497-1500.
5. Plesac TP, Hunt JL. KRAS mutation testing in colorectal cancer. Adv Anat Pathol. 2009;16(4):196-203.
6. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999;91(23):2001-2008.
7. Cancer pharmacogenomics. setting a research agenda to accelerate translation workshop. National Cancer Institute.Web site. http://www .team-psa.com/CPSRAAT2009/home.asp. Accessed June 9, 2010.
8. Trans-NCI Pharmacogenomics and Pharmacoepidemiology Working Group (PPWG). National Cancer Institute. Web site. http://epi.grants .cancer.gov/pharm/ppwg. html. Updated May 11, 2010. Accessed June 9, 2010.
9. Evaluation of Genomic Applications in Practice and Prevention (EGAPP). Centers for Disease Control and Prevention. Web site. http://www.egappreviews. org. Updated May 3, 2010. Accessed June 9, 2010.
10. Human Genome Epidemiology Network (HuGENet). Centers for Disease Control and Prevention. Web site. http://www.cdc.gov/ genomics/hugenet/default.htm. Updated April 14, 2010. Accessed June 9, 2010.
11. Khoury MJ, Feero WG, Reyes M, et al. The Genomic Applications in Practice and Prevention Network. GAPPNet Planning Group. Genet Med. 2009;11(7):488-494.
12. Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB). Stanford University. Web site. http://www.pharmgkb.org. Accessed June 9, 2010.
13. Community Clinical Oncology Program (CCOP). National Cancer Institute. Web site. http://dcp.cancer.gov/programs-resources/programs /ccop. Accessed September 27, 2010.
14. Clinical Trials Cooperative Group Program. National Cancer Institute. Web site. http://dctd.cancer.gov/MajorInitiatives/06CTEPCoopGrps. htm. Accessed June 9, 2010.
15. Specialized Programs of Research Excellence (SPOREs). National Cancer Institute. Web site. http://spores.nci.nih.gov. Accessed June 9, 2010.
16. Cancer Centers Program. National Cancer Institute. Web site. http: //cancercenters.cancer.gov/. Accessed September 27, 2010.
17. Allegra CJ, Jessup JM, Somerfeld MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27(12):2091-2096.
18. Pharmacogenetics Research Network (PGRN). http://www.nigms.nih .gov/Initiatives/PGRN. National Institute of General Medical Sciences Web site. Updated May 18, 2010. Accessed June 9, 2010.
19. Center for Genomic Medicine (CGM). RIKEN Yokohama Institute. Web site. http://www.src.riken.jp/english/. Accessed September 27, 2010.
20. Ingle JN, Schaid DJ, Goss PE, et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol. Published online on September 27, 2010; DOI:10.1200/JCO.2010.28.5064.
21. The Breast Cancer Intergroup of North America (TBCI). National Cancer Institute. Web site. http://ctep.cancer.gov/investigatorResources/ tbci. Updated June 22, 2009. Accessed June 9, 2010.
22. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of effcacy and hot fashes. J Clin Oncol. 2005;23(36):9312-9318.
23. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101(1):113-121.
24. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007;25(33):5187-5193.
25. Lim HS, Ju Lee H, Seok Lee K, et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol. 2008;25(25):3837-3845.
26. Xu Y, Sun Y, Yao L, et al. Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol. 2008;19(8):1423-1429.
27. Kiyotani K, Mushiroda T, Sasa M, et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant ta-moxifen therapy. Cancer Sci. 2008;99(5):995-999.
28. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polypmorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302(13):1429-1436.
29. Ross CJ, Katzov-Eckert H, Dubé MP, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. CPNDS Consortium. Nat Genet. 2009;41(12):1345-1349.
30. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649-659.
31. HMO Research Network. Web site. http://www.hmoresearchnetwork. org. Accessed June 9, 2010.
32. Cancer Registries and Other Population-Based Resources. National Cancer Institute. Web site. http://riskfactor.cancer.gov/tools/pharmaco /registries.html. Updated May 26, 2009. Accessed June 9, 2010.
33. Doroshow JH. NCI's roadmap to personalized cancer treatment. Talk presented at: National Cancer Institute Board of Scientifc Advisors Meeting; June 22, 2009, Bethesda, MD. Web site. http://deainfo.nci.nih. gov/Advisory/bsa/bsa0609/presentations/1100%20Doroshow.ppt. Accessed September 27, 2010.
34. Comparative Effectiveness Research in Genomics and Personalized Medicine. National Cancer Institute. Web site. http://cancercontrol. cancer.gov/od/phg/ research.asp?type=CER. Updated February 24, 2010. Accessed September 27, 2010.
35. Biomedical Informatics Grid (BIG) Health Consortium. http://big healthconsortium.org/about/cabig.asp. Accessed June 9, 2010.
36. Cancer Informatics Biomedical Grid (caBIG) Community. National Cancer Institute. Web site. https://cabig.nci.nih.gov. Accessed June 9, 2010.